Moreover, existing studies suggest that repressing NLRP3 inflammasome can ameliorate intestinal inflammatory injury (Gong et al., 2018; Shao et al., 2019; Cao et al., 2020) as well as CPT-11-induced colitis (Li et al., 2015; Huang et al., 2020). The gene discussed is NLRP3; the disease is colitis.